Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Breast Cancer Research

Fig. 2

From: Roles of BCCIP deficiency in mammary tumorigenesis

Fig. 2

K14-Cre-mediated BCCIP conditional knockdown in the mouse mammary epithelium. a Strategy of Cre-mediated BCCIP knockdown. In the U6-LoxPshBCCIP construct, the U6 promoter that normally drives expression of shRNA is nonfunctional due to insertion of a LoxPNeoLoxP cassette, which can be “popped out” by expression of Cre recombinase. This allows the U6 promoter to reconstitute its activity, leading to the expression of the anti-BCCIP shRNA. b The hK14-Cre transgene and the LoxPshBCCIP cassette were detected in genomic DNA isolated from mammary gland tissue (top and center). PCR amplification of the recombined shBCCIP-expressing cassette was only detected in animals positive for the Cre-recombinase transgene (bottom). c Serial sections of formalin-fixed paraffin-embedded tissues were stained to assess BCCIP levels and corresponding Cre-recombinase expression in the mammary epithelium. Tissue sections from BCCIP-CON and BCCIP-CKD were mounted on the same slide and treated under the same conditions simultaneously. Left two panels show Cre-recombinase, right two panels show characteristic mBCCIP stain for the corresponding serial section. BCCIP BRCA2 and CDKN1A interacting protein, BCCIP-CKD FVB:LoxPshBCCIP +/− ;K14-Cre +/−, BCCIP-CON FVB:LoxPshBCCIP +/− ;K14-Cre −/−

Back to article page